Fig. 2From: The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headacheIndividual and mean (filled square) flow velocities (cm/s) in the middle cerebral arteries (VMCA) on placebo day compared with BGC20-1531 before and after Prostaglandin E2 (PGE2) infusion. There was no difference between AUCVMCA on placebo and BGC20-1531 200 or 400 mg pretreatment (paired t test)Back to article page